The chemotherapeutic resistance-related genes (mainly AKT1 and ERBB1) and EGFR tyrosine kinase inhibitor-related genes were decreased in the effective group, and multiple tumor driver genes (mainly Myc) were increased in the ineffective group (Figure 2B). The gene discussed is MYC; the disease is neoplasm.